Pyxis Oncology (NASDAQ:PYXS) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Pyxis Oncology (NASDAQ:PYXS) announced its quarterly earnings data on Tuesday. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.01, Zacks reports.

Pyxis Oncology Trading Up 1.4 %

Shares of PYXS stock traded up $0.02 on Wednesday, reaching $1.08. The company’s stock had a trading volume of 77,856 shares, compared to its average volume of 613,822. The stock’s fifty day simple moving average is $1.35 and its 200-day simple moving average is $2.40. Pyxis Oncology has a 1 year low of $0.99 and a 1 year high of $6.18. The company has a market capitalization of $63.93 million, a price-to-earnings ratio of -1.04 and a beta of 1.11.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pyxis Oncology stock. Bank of America Corp DE raised its holdings in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 20.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 53,745 shares of the company’s stock after purchasing an additional 9,062 shares during the quarter. Bank of America Corp DE owned 0.09% of Pyxis Oncology worth $84,000 at the end of the most recent reporting period. Institutional investors own 39.09% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on PYXS shares. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Pyxis Oncology in a research report on Wednesday. Royal Bank of Canada restated an “outperform” rating and set a $8.00 target price on shares of Pyxis Oncology in a research note on Wednesday. Finally, William Blair cut shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Pyxis Oncology currently has an average rating of “Moderate Buy” and an average price target of $9.20.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.